SCHEMBL5240709

SCHEMBL5240709

CC(C)(C)c1ccc(C(=O)Nc2cc(-c3cn4ccnc4c(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)ccc2F)cc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BTK Q06187 19/20 0.64
SYK P43405 1/20 0.59
JAK2 O60674 1/20 0.51
INSR P06213 1/20 0.51
IGF1R P08069 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C8 P10632 1/20 0.51
CYP2C9 P11712 1/20 0.51
SRC P12931 1/20 0.51
CYP2C19 P33261 1/20 0.51
FLT3 P36888 1/20 0.51
TEC P42680 1/20 0.51
TXK P42681 1/20 0.51
MAPKAPK2 P49137 1/20 0.51
BMX P51813 1/20 0.51
JAK3 P52333 1/20 0.51
ITK Q08881 1/20 0.51
MAPKAPK3 Q16644 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5238055 0.93 BTK (0.66) BTKSYKJAK2INSRIGF1R
SCHEMBL2216019 0.88 BTK (0.77) BTKSYK
SCHEMBL2218466 0.88 BTK (0.70) BTKSYK
SCHEMBL5277544 0.87 SYK (0.77) BTKSYK
SCHEMBL1070465 0.87 BTK (0.66) BTKSYKJAK2INSRIGF1R
SCHEMBL5241034 0.85 BTK (0.60) BTKSYK
SCHEMBL5237944 0.85 BTK (0.60) BTKSYK
SCHEMBL1070103 0.85 BTK (0.76) BTKJAK2INSRIGF1RCYP3A4
SCHEMBL5240398 0.84 BTK (0.56) BTKSYKJAK2INSRIGF1R
SCHEMBL5240818 0.84 BTK (0.56) BTKSYKJAK2INSRIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812442-A2 IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY CGI Pharmaceuticals, Inc. (US) 2007-08-01 EP claimed
US-20060178367-A1 Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof CGI PHARMACEUTICALS, INC. 2006-08-10 US claimed
WO-2006053121-A2 IMIDAZO[1 , 2-A] PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY CGI PHARMACEUTICALS, INC. (US) 2006-05-18 WO claimed
EP-1812442-A2 IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY CGI Pharmaceuticals, Inc. (US) 2007-08-01 EP disclosed
US-20060178367-A1 Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof CGI PHARMACEUTICALS, INC. 2006-08-10 US disclosed
WO-2006053121-A2 IMIDAZO[1 , 2-A] PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY CGI PHARMACEUTICALS, INC. (US) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178367-A1 Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof BTK, SYK, LCK BTK 1/4885SYK 2/4885JAK2 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.